CSPC Pharmaceutical Group (HKG:1093) said its cervical cancer drug received a Fast Track designation by the US Food and Drug Administration, according to a Wednesday filing with the Hong Kong bourse.
CRB-701, which recently completed enrollment in the dose escalation part of its Phase I clinical trial, is meant to treat relapsed or refractory metastatic cervical cancer, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments